Stents

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those whose treatment fol...

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a higher quality of life than a best-in-class, permanent,...

September 26, 2014 — In response to new science showing that complete revascularization of all significantly blocked arteries leads to better outcomes in some heart attack patients, the American College of Cardiology (ACC) has withdrawn its Choosi...

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE...

Boston Scientific, EVOLVE II, Synergy, bioresorbable stent
In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific Synergy everolimus-eluting bioabsorbable polymer platinum...
stents, Cobra, celonova
CeloNova BioSciences, Inc., announced that positive first-in-man (FIM) clinical trial results found its Cobra PzF coronary stent system with an advanced nano-...
DAPT study
Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop...
Stentys, coronary stent, MiStent SES, Micell Technologies Inc.
Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent...
The Abbott family of Xience everolimus-eluting coronary stents—including the Xience V, Xience nano, Xience Prime, Xience Xpedition, and
MicroVention Inc.’s Low-Profile Visualized Intraluminal Support Device (LVIS and LVIS Jr.) is a stent and delivery system used to...
Boston Scientific received U.S. Food and Drug Administration (FDA) approval for the Rebel platinum chromium coronary stent system, the...

Articles

DAPT study
Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop...
VIVA, VIVA Physicians, Peripheral, Carotid Artery Device, clinical trial results
Viva Physicians, a not-for-profit organization in the field of vascular medicine and intervention, announce clinical trial results and other new happenings at...
October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is...
Earlier this year, the Barnes-Jewish Hospital at Washington University School of Medicine in St. Louis adopted the instant wave-Free Ratio (iFR) technology....

Video Center

There were a few intriguing technology trends at the Radiological Society of North America (RSNA)...
2 days 7 hours ago
All major technology advances in the world of radiology, including cardiac imaging, are unveiled or...
3 weeks 6 days ago
By Dave Fornell, editor of DAIC Magazine The key take away messages from the 26th annual...
12 weeks 2 days ago
The CME webinar "State of the Art in MRI Pediatric Brain Perfusion Imaging" will educate participants in the state of the art clinical and emerging...
This webinar discusses why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient and...
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...